Systematic Review of Semaglutide-Associated Kidney Injury Case Reports

Xian Xiu's systematic review, published on figshare in June 2026, summarizes 20 reported cases of kidney injury associated with the drug semaglutide. The document compiles clinical and laboratory features from 18 studies retrieved from multiple databases up to October 2025. It includes patient demographics, dosing information, adverse reaction types, diagnostic methods, and outcomes.

Use Cases

• Identify risk factors for semaglutide-associated kidney injury based on patient demographics and pre-existing conditions mentioned in the review.
• Analyze the spectrum and timing of adverse renal events based on reported clinical manifestations and dosage information.
• Study diagnostic pathways for drug-induced kidney injury based on the reported use of renal biopsy versus functional parameters.
• Assess recovery outcomes following semaglutide-associated kidney injury based on the reported patient outcomes.

Strengths

• Includes 20 individual patient cases from a systematic search of multiple databases.
• Reports specific dosage ranges (0.25 to 2.0 mg) and patient age range (29 to 83 years).
• Documents diagnostic methods, with 12 cases confirmed by renal biopsy.
• Provides outcome data, with 17 of 20 patients showing improvement or recovery.

Limitations

• The dataset is a 13.4 KB DOCX document; its structured data content and column definitions are unknown.
• Row count for any underlying tabular data is unspecified, limiting scale assessment.
• The data is derived from published case reports, which may reflect reporting bias inherent to the literature.

Provenance

Source

Author Xian Xiu, published on figshare.

Collection Method

Systematic review of case reports and case series retrieved from PubMed/MEDLINE, Web of Science, Embase, Cochrane Library, and CNKI.

Time Range

Literature search from database inception to October 31, 2025.

Freshness

Last updated 2026-06-01 04:18:55.

Geography

Studies published in English and Chinese; geographic coverage of patients is not specified.